CN103998061A - 使用木糖醇稳定的依那西普制剂 - Google Patents

使用木糖醇稳定的依那西普制剂 Download PDF

Info

Publication number
CN103998061A
CN103998061A CN201280062739.4A CN201280062739A CN103998061A CN 103998061 A CN103998061 A CN 103998061A CN 201280062739 A CN201280062739 A CN 201280062739A CN 103998061 A CN103998061 A CN 103998061A
Authority
CN
China
Prior art keywords
peak
amount
embrel
hic
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280062739.4A
Other languages
English (en)
Chinese (zh)
Inventor
马克·曼宁
布莱恩·墨菲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ke Rongsheng Biological Science Co Ltd
Original Assignee
Ke Rongsheng Biological Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ke Rongsheng Biological Science Co Ltd filed Critical Ke Rongsheng Biological Science Co Ltd
Publication of CN103998061A publication Critical patent/CN103998061A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
CN201280062739.4A 2011-10-18 2012-10-18 使用木糖醇稳定的依那西普制剂 Pending CN103998061A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161548518P 2011-10-18 2011-10-18
US61/548,518 2011-10-18
US201261669480P 2012-07-09 2012-07-09
US61/669,480 2012-07-09
PCT/US2012/060745 WO2013059410A1 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with xylitol

Publications (1)

Publication Number Publication Date
CN103998061A true CN103998061A (zh) 2014-08-20

Family

ID=48136153

Family Applications (6)

Application Number Title Priority Date Filing Date
CN201280062761.9A Pending CN104010658A (zh) 2011-10-18 2012-10-18 使用葡甲胺稳定的依那西普制剂
CN201280062747.9A Expired - Fee Related CN104010654B (zh) 2011-10-18 2012-10-18 金属离子稳定的依那西普制剂
CN201280062739.4A Pending CN103998061A (zh) 2011-10-18 2012-10-18 使用木糖醇稳定的依那西普制剂
CN201280062748.3A Pending CN104010657A (zh) 2011-10-18 2012-10-18 氯化钠稳定的依那西普制剂
CN201280062418.4A Expired - Fee Related CN103998060B (zh) 2011-10-18 2012-10-18 使用糖与多元醇的结合物稳定的依那西普制剂
CN201280062758.7A Expired - Fee Related CN104011073B (zh) 2011-10-18 2012-10-18 使用氨基酸稳定的依那西普制剂

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201280062761.9A Pending CN104010658A (zh) 2011-10-18 2012-10-18 使用葡甲胺稳定的依那西普制剂
CN201280062747.9A Expired - Fee Related CN104010654B (zh) 2011-10-18 2012-10-18 金属离子稳定的依那西普制剂

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201280062748.3A Pending CN104010657A (zh) 2011-10-18 2012-10-18 氯化钠稳定的依那西普制剂
CN201280062418.4A Expired - Fee Related CN103998060B (zh) 2011-10-18 2012-10-18 使用糖与多元醇的结合物稳定的依那西普制剂
CN201280062758.7A Expired - Fee Related CN104011073B (zh) 2011-10-18 2012-10-18 使用氨基酸稳定的依那西普制剂

Country Status (28)

Country Link
US (21) US9302002B2 (enExample)
EP (6) EP2768525B1 (enExample)
JP (6) JP6104922B2 (enExample)
KR (7) KR20140091707A (enExample)
CN (6) CN104010658A (enExample)
AR (6) AR088381A1 (enExample)
AU (6) AU2012326084B2 (enExample)
BR (6) BR112014009131A8 (enExample)
CA (6) CA2851642A1 (enExample)
CY (1) CY1121843T1 (enExample)
DK (1) DK2768525T3 (enExample)
EA (6) EA028520B1 (enExample)
ES (1) ES2734070T3 (enExample)
HK (3) HK1200718A1 (enExample)
HR (1) HRP20191215T1 (enExample)
HU (1) HUE045624T2 (enExample)
IL (6) IL231826A0 (enExample)
IN (3) IN2014CN02527A (enExample)
LT (1) LT2768525T (enExample)
MX (7) MX2014004733A (enExample)
PL (1) PL2768525T3 (enExample)
PT (1) PT2768525T (enExample)
RS (1) RS59179B1 (enExample)
SG (6) SG11201401562RA (enExample)
SI (1) SI2768525T1 (enExample)
SM (1) SMT201900422T1 (enExample)
TW (6) TW201325606A (enExample)
WO (6) WO2013059412A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104694355A (zh) * 2015-03-20 2015-06-10 吉林大学 葛根护肝保健酒及其制备方法

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
US9302002B2 (en) * 2011-10-18 2016-04-05 Coherus Biosciences, Inc. Etanercept formulations stabilized with combinations of sugars and polyols
CA2878508A1 (en) 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
PL2895188T3 (pl) * 2012-09-11 2018-06-29 Coherus Biosciences, Inc. Prawidłowo pofałdowany etanercept o wysokiej czystości i doskonałej wydajności
HK1221163A1 (zh) * 2013-05-02 2017-05-26 Mabxience, S.A. Tnfr:fc融合多肽的替代配方
WO2015056613A1 (ja) * 2013-10-15 2015-04-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 安定化されたポリペプチド水性製剤
CA2926089C (en) * 2013-10-24 2022-08-30 Medimmune, Llc Stable, aqueous antibody formulations
JP6798882B2 (ja) 2013-11-29 2020-12-09 アレス トレーディング ソシエテ アノニム ＴＮＦＲ及びＦｃ領域を含む融合タンパク質の液体製剤
IS3008B (is) * 2014-05-14 2018-12-15 Calor ehf Stöðgandi lausnir fyrir prótín og peptíð
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
JP6781508B2 (ja) 2014-11-18 2020-11-04 塩野義製薬株式会社 安定化されたペプチド組成物
AU2015371381A1 (en) * 2014-12-22 2017-07-20 Ares Trading S.A. Liquid pharmaceutical composition
EP3236942A1 (en) * 2014-12-23 2017-11-01 Drug Discovery Laboratory AS Protein compositions and use thereof
US10988527B2 (en) 2014-12-31 2021-04-27 Lg Chem, Ltd. Method for preparing TNFR-Fc fusion protein containing target content of impurities
MX389818B (es) * 2015-08-13 2025-03-20 Landsteiner Scient S A De C V Composicion de estabilidad mejorada de etanercept.
JP5938762B1 (ja) * 2015-09-01 2016-06-22 日揮株式会社 マイクロカプセル製剤及びその製造方法
CN105748414A (zh) * 2016-03-02 2016-07-13 张光泉 抗感染米卡芬净冻干组合物及其制备方法
JPWO2017179683A1 (ja) * 2016-04-15 2019-02-21 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ミカファンギンの安定化された医薬組成物
US20180110856A1 (en) * 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical Formulations and Methods of Making the Same
US11236146B2 (en) 2016-10-28 2022-02-01 Celltrion Inc. Stable pharmaceutical formulation
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
MX2017013995A (es) * 2017-10-31 2019-05-01 Probiomed S A De C V Formulacion farmaceutica estable de una proteina de fusion.
KR20200093628A (ko) * 2017-11-30 2020-08-05 바이오-테라 솔루션즈 리미티드 Il-6 관련 질병을 치료하는 인간화항체의 액체 제제
WO2019124946A1 (ko) * 2017-12-22 2019-06-27 삼성바이오에피스 주식회사 Vegf 길항제를 포함하는 액상 조성물
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
CN111228225B (zh) * 2018-11-28 2022-08-26 鲁南制药集团股份有限公司 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂
GB201911461D0 (en) 2019-08-09 2019-09-25 Arecor Ltd Novel composition
EP4065166A4 (en) * 2019-11-26 2023-12-20 Comera Life Sciences, Inc. EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONS
IL305010A (en) 2021-02-17 2023-10-01 Arecor Ltd An aqueous preparation of a transgenic protein structure that includes an FC domain
CN114788809B (zh) * 2022-01-25 2023-04-14 江苏广承药业有限公司 一种氯雷他定液体制剂

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1244805A (zh) * 1996-11-19 2000-02-16 罗赫诊断器材股份有限公司 冷冻干燥的稳定的单克隆或多克隆抗体药物制剂
US20030180287A1 (en) * 2002-02-27 2003-09-25 Immunex Corporation Polypeptide formulation
CN1829739A (zh) * 2003-08-01 2006-09-06 安美基公司 结晶肿瘤坏死因子受体2多肽
US7294481B1 (en) * 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
CN101237890A (zh) * 2005-06-10 2008-08-06 中外制药株式会社 含有葡甲胺的蛋白质制剂的稳定剂及其利用
US20100158908A1 (en) * 2006-10-20 2010-06-24 Amgen Inc. Stable Polypeptide Formulations
CN103930124A (zh) * 2011-07-01 2014-07-16 生物基因Idecma公司 无精氨酸的tnfr：fc-融合多肽组合物及使用方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
NZ256293A (en) 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6677326B2 (en) * 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
CA2366785C (en) * 1999-04-19 2012-02-07 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
WO2001058473A1 (en) 2000-02-10 2001-08-16 Wyeth Method of treating or inhibiting cellular injury or cell death
DK1314437T3 (da) 2000-08-11 2014-07-14 Chugai Pharmaceutical Co Ltd Stabiliserede antistofindeholdende præparater
US6936437B2 (en) * 2001-02-23 2005-08-30 Lucia Irene Gonzalez-Villasenor Methods and compositions for production of recombinant peptides
CN100563712C (zh) * 2003-02-28 2009-12-02 阿雷斯贸易股份有限公司 肿瘤坏死因子结合蛋白的液体制剂
WO2004082715A1 (ja) 2003-03-20 2004-09-30 Eisai Co., Ltd. 炎症性腸疾患治療剤としての併用医薬
EP1680137B1 (en) 2003-10-14 2012-11-21 F. Hoffmann-La Roche Ltd. Macrocyclic carboxylic acid and acylsulfonamide compound as inhibitor of HCV replication
JP5554466B2 (ja) 2004-03-01 2014-07-23 味の素株式会社 抗ヒトＴＮＦ−α抗体活性低下抑制剤
EP1720972B1 (en) 2004-03-05 2014-01-08 DSM IP Assets B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006138181A2 (en) * 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
CN101584858A (zh) 2005-12-20 2009-11-25 布里斯托尔-迈尔斯斯奎布公司 稳定蛋白质制剂
CN101378782A (zh) * 2005-12-21 2009-03-04 惠氏公司 粘度降低的蛋白质制剂及其用途
US20080071063A1 (en) 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
AU2007227292B2 (en) * 2006-03-17 2012-04-12 Biogen Ma Inc. Stabilized polypeptide compositions
US20100016677A1 (en) 2006-03-21 2010-01-21 Eugen Oetringer Devices for and Methods of Analyzing a Physiological Condition of a Physiological Subject Based on A Workload Related Property
MX2008013535A (es) 2006-04-21 2008-10-29 Amgen Inc Agentes amortiguadores para formulaciones biofarmaceuticas.
AU2007321877B2 (en) * 2006-08-01 2011-11-03 Kineta Two, Llc Pharmaceutical manufacturing methods
US20080112953A1 (en) * 2006-10-06 2008-05-15 Amgen Inc. Stable formulations
EP2064315B1 (en) 2006-11-03 2015-05-13 Wyeth LLC Glycolysis-inhibiting substances in cell culture
JP5577098B2 (ja) * 2006-12-21 2014-08-20 アムジエン・インコーポレーテツド ポリペプチドを含有する安定な緩衝化された製剤
US9012180B2 (en) 2007-03-02 2015-04-21 Wyeth Llc Use of copper and glutamate in cell culture for production of polypeptides
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
BRPI0814252B8 (pt) 2007-06-14 2021-05-25 Biogen Idec Inc composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia
KR20150080038A (ko) 2007-11-30 2015-07-08 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
KR20100120289A (ko) * 2008-01-15 2010-11-15 애보트 게엠베하 운트 콤파니 카게 분말상 단백질 조성물 및 이의 제조 방법
CA2717129A1 (en) 2008-02-29 2009-09-11 Biogen Idec Ma Inc. Purified immunoglobulin fusion proteins and methods of their purification
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
HRP20200768T4 (hr) 2009-08-11 2025-03-28 F. Hoffmann - La Roche Ag Proizvodnja proteina u mediju za uzgoj stanica bez glutamina
WO2011049798A1 (en) 2009-10-20 2011-04-28 Merck Sharp & Dohme Corp. Use of mixed mode chromatography for the capture and purification of basic antibody products
US20130052195A1 (en) * 2009-12-23 2013-02-28 Emergent Product Development Seattle,LLC Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
CN102858952B (zh) 2010-04-26 2015-10-14 诺瓦提斯公司 改进的细胞培养基
RU2600847C2 (ru) * 2010-05-10 2016-10-27 Интас Биофармасьютикалс Лимитед Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина
WO2012013980A1 (en) * 2010-07-30 2012-02-02 Arecor Limited Stabilized aqueous antibody compositions
JP2013535981A (ja) 2010-08-20 2013-09-19 ワイス・エルエルシー 成長因子不含適合細胞の細胞培養
SG187885A1 (en) 2010-08-31 2013-03-28 Friesland Brands Bv Culture medium for eukaryotic cells
CA2813747A1 (en) 2010-10-11 2012-04-19 Chen Wang Processes for purification of proteins
WO2012143418A1 (en) * 2011-04-20 2012-10-26 Sandoz Ag STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
CA2840626A1 (en) 2011-06-29 2013-01-03 Insite Vision Incorporated Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
JP5897708B2 (ja) 2011-07-01 2016-03-30 アムジエン・インコーポレーテツド 哺乳類細胞培養物
US9781540B2 (en) * 2011-07-07 2017-10-03 Qualcomm Incorporated Application relevance determination based on social context
AU2012282960A1 (en) 2011-07-08 2014-01-16 Merck Sharp & Dohme Corp. Method for purifying Fc-fusion protein
ES2651483T3 (es) 2011-08-17 2018-01-26 Ares Trading S.A. Método para preparar la forma activa de la proteína de fusión TNRF-Fc
US9302002B2 (en) * 2011-10-18 2016-04-05 Coherus Biosciences, Inc. Etanercept formulations stabilized with combinations of sugars and polyols
PL2895188T3 (pl) 2012-09-11 2018-06-29 Coherus Biosciences, Inc. Prawidłowo pofałdowany etanercept o wysokiej czystości i doskonałej wydajności

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1244805A (zh) * 1996-11-19 2000-02-16 罗赫诊断器材股份有限公司 冷冻干燥的稳定的单克隆或多克隆抗体药物制剂
US7294481B1 (en) * 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US20030180287A1 (en) * 2002-02-27 2003-09-25 Immunex Corporation Polypeptide formulation
CN1829739A (zh) * 2003-08-01 2006-09-06 安美基公司 结晶肿瘤坏死因子受体2多肽
CN101237890A (zh) * 2005-06-10 2008-08-06 中外制药株式会社 含有葡甲胺的蛋白质制剂的稳定剂及其利用
US20100158908A1 (en) * 2006-10-20 2010-06-24 Amgen Inc. Stable Polypeptide Formulations
CN103930124A (zh) * 2011-07-01 2014-07-16 生物基因Idecma公司 无精氨酸的tnfr：fc-融合多肽组合物及使用方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104694355A (zh) * 2015-03-20 2015-06-10 吉林大学 葛根护肝保健酒及其制备方法

Also Published As

Publication number Publication date
US20190184017A1 (en) 2019-06-20
EA025663B1 (ru) 2017-01-30
CN104010654A (zh) 2014-08-27
EP2768532A1 (en) 2014-08-27
MX2019009176A (es) 2019-10-07
MX2014004728A (es) 2015-05-15
TW201325610A (zh) 2013-07-01
AR088460A1 (es) 2014-06-11
JP6113176B2 (ja) 2017-04-12
HK1200722A1 (en) 2015-08-14
AU2012326168A1 (en) 2014-04-24
TWI595883B (zh) 2017-08-21
AU2012326084B2 (en) 2016-12-15
KR20140091707A (ko) 2014-07-22
ES2734070T3 (es) 2019-12-04
JP6199298B2 (ja) 2017-09-20
TW201325609A (zh) 2013-07-01
SMT201900422T1 (it) 2019-09-09
EP2768535A4 (en) 2015-03-11
PL2768525T3 (pl) 2019-10-31
EP2768531A4 (en) 2015-03-11
KR102163150B1 (ko) 2020-10-08
EA201490817A1 (ru) 2014-09-30
EA026410B1 (ru) 2017-04-28
SG11201401576WA (en) 2014-10-30
US9302002B2 (en) 2016-04-05
TWI619504B (zh) 2018-04-01
SG11201401562RA (en) 2014-09-26
TW201325608A (zh) 2013-07-01
US20190298837A1 (en) 2019-10-03
US10987405B2 (en) 2021-04-27
CN104010658A (zh) 2014-08-27
HK1200719A1 (en) 2015-08-14
IN2014CN02591A (enExample) 2015-06-26
US20160317667A1 (en) 2016-11-03
TW201325611A (zh) 2013-07-01
EP2768535A1 (en) 2014-08-27
MX2014004733A (es) 2015-05-15
EA027325B1 (ru) 2017-07-31
KR20140091706A (ko) 2014-07-22
JP2014530255A (ja) 2014-11-17
US20190314498A1 (en) 2019-10-17
EP2768854A4 (en) 2015-03-11
KR20140091705A (ko) 2014-07-22
CN104010657A (zh) 2014-08-27
EA201490804A1 (ru) 2014-09-30
HRP20191215T1 (hr) 2019-10-04
JP6220789B2 (ja) 2017-10-25
PT2768525T (pt) 2019-07-17
HUE045624T2 (hu) 2020-01-28
CN103998060A (zh) 2014-08-20
KR20140079491A (ko) 2014-06-26
EA025267B1 (ru) 2016-12-30
US10376588B2 (en) 2019-08-13
US10213508B2 (en) 2019-02-26
SG11201401563SA (en) 2014-09-26
KR20200008021A (ko) 2020-01-22
IL231827A0 (en) 2014-05-28
CA2851628A1 (en) 2013-04-25
BR112014009073A2 (pt) 2017-05-09
SG11201401519RA (en) 2014-07-30
EP2768854A1 (en) 2014-08-27
US10888619B2 (en) 2021-01-12
CN104011073A (zh) 2014-08-27
EA028520B1 (ru) 2017-11-30
WO2013059408A1 (en) 2013-04-25
AU2012326082B2 (en) 2016-12-15
US20190290765A1 (en) 2019-09-26
CA2851646A1 (en) 2013-04-25
US9801942B2 (en) 2017-10-31
AR088382A1 (es) 2014-05-28
IL231829A0 (en) 2014-05-28
EA201490801A1 (ru) 2014-09-30
MX2014004734A (es) 2015-05-15
BR112014009146A2 (pt) 2017-06-13
AU2012326171A1 (en) 2014-04-24
AU2012326082A1 (en) 2014-04-24
EP2768533A1 (en) 2014-08-27
AU2012326080B2 (en) 2017-02-16
US20190290766A1 (en) 2019-09-26
CA2851642A1 (en) 2013-04-25
EP2768531A1 (en) 2014-08-27
KR102068462B1 (ko) 2020-01-22
HK1200720A1 (en) 2015-08-14
US20190216930A1 (en) 2019-07-18
WO2013059412A1 (en) 2013-04-25
HK1200851A1 (en) 2015-08-14
EP2768525A4 (en) 2015-07-15
AU2012326170A1 (en) 2014-04-24
US20130108633A1 (en) 2013-05-02
EA201490815A1 (ru) 2014-09-30
DK2768525T3 (da) 2019-07-22
KR20140097184A (ko) 2014-08-06
AR088380A1 (es) 2014-05-28
AR088383A1 (es) 2014-05-28
BR112014009031A2 (pt) 2017-05-09
SG11201401567YA (en) 2014-07-30
CA2851639A1 (en) 2013-04-25
SG11201401517VA (en) 2014-09-26
US20130101640A1 (en) 2013-04-25
HK1200718A1 (en) 2015-08-14
AU2012326170B2 (en) 2016-12-22
US20190290767A1 (en) 2019-09-26
US11135267B2 (en) 2021-10-05
US20130101584A1 (en) 2013-04-25
CA2851635A1 (en) 2013-04-25
WO2013059407A1 (en) 2013-04-25
TW201325607A (zh) 2013-07-01
JP2014530254A (ja) 2014-11-17
EP2768525B1 (en) 2019-06-19
BR112014009087A2 (pt) 2017-04-18
AU2012326171B2 (en) 2017-03-09
SI2768525T1 (sl) 2019-10-30
CA2851651A1 (en) 2013-04-25
CN104010654B (zh) 2017-10-27
BR112014009131A8 (pt) 2017-06-20
US20160199489A1 (en) 2016-07-14
CA2851639C (en) 2020-12-29
WO2013059406A1 (en) 2013-04-25
TW201325606A (zh) 2013-07-01
EA201490802A1 (ru) 2014-08-29
BR112014009022A2 (pt) 2017-05-02
US20180125982A1 (en) 2018-05-10
CN103998060B (zh) 2016-12-21
IL231826A0 (en) 2014-05-28
CN104011073B (zh) 2017-08-25
IN2014CN02527A (enExample) 2015-06-26
JP2014530864A (ja) 2014-11-20
MX2014004732A (es) 2015-05-15
US10980885B2 (en) 2021-04-20
US9943601B2 (en) 2018-04-17
TWI644681B (zh) 2018-12-21
BR112014009131A2 (pt) 2017-06-13
US10980884B2 (en) 2021-04-20
JP2014530256A (ja) 2014-11-17
IL231825A0 (en) 2014-05-28
EA201490803A1 (ru) 2014-09-30
JP6220788B2 (ja) 2017-10-25
HK1200721A1 (en) 2015-08-14
KR20140083037A (ko) 2014-07-03
IN2014CN02592A (enExample) 2015-09-04
AR088381A1 (es) 2014-05-28
EP2768533A4 (en) 2015-03-11
BR112014009146A8 (pt) 2017-06-20
MX367054B (es) 2019-08-02
JP6110393B2 (ja) 2017-04-05
EP2768532A4 (en) 2015-03-11
US20180028668A1 (en) 2018-02-01
WO2013059410A1 (en) 2013-04-25
MX2014004725A (es) 2015-02-05
LT2768525T (lt) 2019-09-25
US11129876B2 (en) 2021-09-28
AR088379A1 (es) 2014-05-28
US10293049B2 (en) 2019-05-21
US9393305B2 (en) 2016-07-19
US20190328875A1 (en) 2019-10-31
WO2013059405A1 (en) 2013-04-25
RS59179B1 (sr) 2019-10-31
US20200405865A1 (en) 2020-12-31
US10772963B2 (en) 2020-09-15
US20190314500A1 (en) 2019-10-17
US9770510B2 (en) 2017-09-26
IL231828A0 (en) 2014-05-28
US20190314499A1 (en) 2019-10-17
AU2012326080A1 (en) 2014-04-24
JP2014530862A (ja) 2014-11-20
US20180193463A1 (en) 2018-07-12
MX2014004726A (es) 2015-05-15
IL231824A0 (en) 2014-05-28
JP2014530863A (ja) 2014-11-20
EP2768525A1 (en) 2014-08-27
CY1121843T1 (el) 2020-07-31
JP6104922B2 (ja) 2017-03-29
US20190290768A1 (en) 2019-09-26
US20130108632A1 (en) 2013-05-02
AU2012326084A1 (en) 2014-04-17
AU2012326168B2 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
CN103998061A (zh) 使用木糖醇稳定的依那西普制剂
US11000588B2 (en) Etanercept formulations stabilized with sodium chloride
HK1200720B (en) Etanercept formulations stabilized with combinations of sugars and polyols

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1200721

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140820

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1200721

Country of ref document: HK